Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
SHANGHAI, May 6, 2026 /PRNewswire/ — Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Co…












